National Institutes of Health (NIH) press release
In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue (sublingual), one of the standard methods of treatment. Additionally, serious adverse events were less common in those receiving extended-release treatment. The findings, which support the use of this formulation of buprenorphine for treating OUD during pregnancy, were published in JAMA Internal Medicine.
Read the full press release here.
Source : National Institutes of Health
Related HIV and Co-Infections News
-
[Press release] Wits University: Landmark South African study shows HPV vaccination protects girls living with HIV
-
UNAIDS: ‘Olimbi – Mother Courage’ HIV documentary wins Geneva film festival Impact Award
-
HIV i-Base: GLP-1 receptor agonists reduce substance use disorder: a role for addiction to chemsex drugs?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.